118 related articles for article (PubMed ID: 37963292)
1. Significance of the Pretreatment Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratios in Predicting the Response to Neoadjuvant Chemotherapy and Survival Rates in Extremity Osteosarcoma: A Multicentre Prospective Study.
Arefpour AM; Garousi M; Foroughi A; Hosseini S; Shahin M; Javadinia SA
Cancer Invest; 2023 Dec; 41(10):816-820. PubMed ID: 37963292
[TBL] [Abstract][Full Text] [Related]
2. Total Neoadjuvant vs. Standard Perioperative Cisplatin/ Doxorubicin Chemotherapy in Patients with Extremities Osteosarcoma: A Multi-Center Cohort Study.
Foroughi A; Arefpour AM; Nikoofar A; Sanei M; Mahdavi SH; Javadinia SA
Asian Pac J Cancer Prev; 2023 Jul; 24(7):2369-2374. PubMed ID: 37505768
[TBL] [Abstract][Full Text] [Related]
3. Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratios can Predict Treatment Response to Neoadjuvant Therapy in Esophageal Cancer.
McLaren PJ; Bronson NW; Hart KD; Vaccaro GM; Gatter KM; Thomas CR; Hunter JG; Dolan JP
J Gastrointest Surg; 2017 Apr; 21(4):607-613. PubMed ID: 28083838
[TBL] [Abstract][Full Text] [Related]
4. Significance of the neutrophil-to-lymphocyte ratio in predicting the response to neoadjuvant chemotherapy in extremity osteosarcoma: a multicentre retrospective study.
Tang H; Liu D; Lu J; He J; Ji S; Liao S; Wei Q; Lu S; Liu Y
BMC Cancer; 2022 Jan; 22(1):33. PubMed ID: 34983443
[TBL] [Abstract][Full Text] [Related]
5. Pretreatment neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios do not predict survival in patients with cervical cancer treated with neoadjuvant chemotherapy and radical hysterectomy.
Wang D; Wu M; Feng FZ; Huang HF; Yang JX; Shen K; Xiang Y
Chin Med J (Engl); 2013; 126(8):1464-8. PubMed ID: 23595378
[TBL] [Abstract][Full Text] [Related]
6. Prechemotherapy neutrophil : lymphocyte ratio is superior to the platelet : lymphocyte ratio as a prognostic indicator for locally advanced esophageal squamous cell cancer treated with neoadjuvant chemotherapy.
Ji WH; Jiang YH; Ji YL; Li B; Mao WM
Dis Esophagus; 2016 Jul; 29(5):403-11. PubMed ID: 25625421
[TBL] [Abstract][Full Text] [Related]
7. Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios as predictors of outcomes in inflammatory breast cancer.
Al Jarroudi O; El Bairi K; Abda N; Zaimi A; Jaouani L; Chibani H; Afqir S
Biomark Med; 2021 Oct; 15(14):1289-1298. PubMed ID: 34486882
[No Abstract] [Full Text] [Related]
8. Platelet/Lymphocyte Ratio Is Superior to Neutrophil/Lymphocyte Ratio as a Predictor of Chemotherapy Response and Disease-free Survival in Luminal B-like (HER2
Hu Y; Wang S; Ding N; Li N; Huang J; Xiao Z
Clin Breast Cancer; 2020 Aug; 20(4):e403-e409. PubMed ID: 32201163
[TBL] [Abstract][Full Text] [Related]
9. Prognostic Value of Platelet-to-Lymphocyte Ratio, Neutrophil-to-Lymphocyte Ratio, and Lymphocyte-to-White Blood Cell Ratio in Colorectal Cancer Patients Who Received Neoadjuvant Chemotherapy.
Jia W; Yuan L; Ni H; Xu B; Zhao P
Technol Cancer Res Treat; 2021; 20():15330338211034291. PubMed ID: 34308689
[TBL] [Abstract][Full Text] [Related]
10. Pretreatment neutrophil-to-lymphocyte ratio is correlated with response to neoadjuvant chemotherapy as an independent prognostic indicator in breast cancer patients: a retrospective study.
Chen Y; Chen K; Xiao X; Nie Y; Qu S; Gong C; Su F; Song E
BMC Cancer; 2016 May; 16():320. PubMed ID: 27198767
[TBL] [Abstract][Full Text] [Related]
11. Association of neutrophil/lymphocyte ratio and platelet/lymphocyte ratio with ER and PR in breast cancer patients and their changes after neoadjuvant chemotherapy.
Xu J; Ni C; Ma C; Zhang L; Jing X; Li C; Liu Y; Qu X
Clin Transl Oncol; 2017 Aug; 19(8):989-996. PubMed ID: 28247194
[TBL] [Abstract][Full Text] [Related]
12. Peripheral Venous Blood Platelet-to-Lymphocyte Ratio (PLR) for Predicting the Survival of Patients With Gastric Cancer Treated With SOX or XELOX Regimen Neoadjuvant Chemotherapy.
Chen L; Hao Y; Cong X; Zou M; Li S; Zhu L; Song H; Xue Y
Technol Cancer Res Treat; 2019 Jan; 18():1533033819829485. PubMed ID: 30760114
[TBL] [Abstract][Full Text] [Related]
13. Predictive values of combined platelet count, neutrophil-lymphocyte ratio, and platelet-lymphocyte ratio in preeclampsia.
Elmaradny E; Alneel G; Alkhattaf N; AlGadri T; Albriakan N
J Obstet Gynaecol; 2022 Jul; 42(5):1011-1017. PubMed ID: 34927550
[TBL] [Abstract][Full Text] [Related]
14. Combination of peripheral neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio is predictive of pathological complete response after neoadjuvant chemotherapy in breast cancer patients.
Graziano V; Grassadonia A; Iezzi L; Vici P; Pizzuti L; Barba M; Quinzii A; Camplese A; Di Marino P; Peri M; Veschi S; Alberti S; Gamucci T; Di Gioacchino M; De Tursi M; Natoli C; Tinari N
Breast; 2019 Apr; 44():33-38. PubMed ID: 30611095
[TBL] [Abstract][Full Text] [Related]
15. Impact of chemotherapy-induced necrosis on event-free and overall survival after preoperative MAP chemotherapy in patients with primary high-grade localized osteosarcoma.
Tsuda Y; Tsoi K; Parry MC; Stevenson JD; Fujiwara T; Sumathi V; Jeys LM
Bone Joint J; 2020 Jun; 102-B(6):795-803. PubMed ID: 32475245
[TBL] [Abstract][Full Text] [Related]
16. Pretreatment neutrophil/lymphocyte, platelet/lymphocyte, lymphocyte/monocyte, and neutrophil/monocyte ratios and outcome in elderly breast cancer patients.
Losada B; Guerra JA; Malón D; Jara C; Rodriguez L; Del Barco S
Clin Transl Oncol; 2019 Jul; 21(7):855-863. PubMed ID: 30506134
[TBL] [Abstract][Full Text] [Related]
17. Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios as predictive and prognostic markers in patients with locally advanced rectal cancer treated with neoadjuvant chemoradiation.
Dudani S; Marginean H; Tang PA; Monzon JG; Raissouni S; Asmis TR; Goodwin RA; Gotfrit J; Cheung WY; Vickers MM
BMC Cancer; 2019 Jul; 19(1):664. PubMed ID: 31277604
[TBL] [Abstract][Full Text] [Related]
18. Platelet and Neutrophil Counts as Predictive Markers of Neoadjuvant Therapy Efficacy in Rectal Cancer.
Policicchio A; Mercier J; Digklia A; Voutsadakis IA
J Gastrointest Cancer; 2019 Dec; 50(4):894-900. PubMed ID: 30353366
[TBL] [Abstract][Full Text] [Related]
19. Nonmetastatic osteosarcoma of the extremity. Neoadjuvant chemotherapy with methotrexate, cisplatin, doxorubicin and ifosfamide. An Italian Sarcoma Group study (ISG/OS-Oss).
Ferrari S; Meazza C; Palmerini E; Tamburini A; Fagioli F; Cozza R; Ferraresi V; Bisogno G; Mascarin M; Cefalo G; Manfrini M; Capanna R; Biagini R; Donati D; Picci P
Tumori; 2014; 100(6):612-9. PubMed ID: 25688494
[TBL] [Abstract][Full Text] [Related]
20. Preoperative independent prognostic factors in patients with borderline resectable pancreatic ductal adenocarcinoma following curative resection: the neutrophil-lymphocyte and platelet-lymphocyte ratios.
Asari S; Matsumoto I; Toyama H; Shinzeki M; Goto T; Ishida J; Ajiki T; Fukumoto T; Ku Y
Surg Today; 2016 May; 46(5):583-92. PubMed ID: 26108488
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
